ATE448312T1 - Leitsequenzen zur verwendung bei der produktion von proteinen - Google Patents

Leitsequenzen zur verwendung bei der produktion von proteinen

Info

Publication number
ATE448312T1
ATE448312T1 AT04787205T AT04787205T ATE448312T1 AT E448312 T1 ATE448312 T1 AT E448312T1 AT 04787205 T AT04787205 T AT 04787205T AT 04787205 T AT04787205 T AT 04787205T AT E448312 T1 ATE448312 T1 AT E448312T1
Authority
AT
Austria
Prior art keywords
proteins
production
dna constructs
leader sequences
guide sequences
Prior art date
Application number
AT04787205T
Other languages
English (en)
Inventor
Philippe Dupraz
Michel Kobr
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE448312T1 publication Critical patent/ATE448312T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04787205T 2003-09-26 2004-09-24 Leitsequenzen zur verwendung bei der produktion von proteinen ATE448312T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03103580 2003-09-26
US50693903P 2003-09-29 2003-09-29
PCT/EP2004/052302 WO2005030963A1 (en) 2003-09-26 2004-09-24 Leader sequences for use in production of proteins

Publications (1)

Publication Number Publication Date
ATE448312T1 true ATE448312T1 (de) 2009-11-15

Family

ID=34924107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04787205T ATE448312T1 (de) 2003-09-26 2004-09-24 Leitsequenzen zur verwendung bei der produktion von proteinen

Country Status (8)

Country Link
US (1) US20070141666A1 (de)
EP (1) EP1670918B1 (de)
JP (1) JP4809227B2 (de)
AT (1) ATE448312T1 (de)
AU (1) AU2004276522B2 (de)
CA (1) CA2537340A1 (de)
ES (1) ES2333724T3 (de)
WO (1) WO2005030963A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4768122B2 (ja) * 1998-02-20 2011-09-07 ユニバーシティー オブ マイアミ 改変型熱ショックタンパク質−抗原性ペプチド複合体
JP4467815B2 (ja) * 2001-02-26 2010-05-26 富士通マイクロエレクトロニクス株式会社 不揮発性半導体メモリの読み出し動作方法および不揮発性半導体メモリ
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
KR20110017356A (ko) 2008-03-20 2011-02-21 유니버시티 오브 마이애미 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
ES2853935T3 (es) 2013-03-12 2021-09-20 Massachusetts Gen Hospital Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
US10258668B2 (en) 2013-09-20 2019-04-16 The General Hospital Corporation Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
BR112017016681A2 (pt) 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
EP3443001B1 (de) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
WO2018112168A1 (en) 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
EP3983538A1 (de) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung
EP3983537A1 (de) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20240166707A1 (en) 2021-01-08 2024-05-23 Strand Therapeutics Inc. Expression constructs and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723662D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
JP2000502704A (ja) 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
WO1999053059A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
ES2257287T3 (es) 1999-02-12 2006-08-01 Amgen Inc. Composiciones de leptina glicosiladas y metodos relacionados.
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies

Also Published As

Publication number Publication date
AU2004276522B2 (en) 2010-12-02
ES2333724T3 (es) 2010-02-26
WO2005030963A1 (en) 2005-04-07
AU2004276522A1 (en) 2005-04-07
JP2007506420A (ja) 2007-03-22
US20070141666A1 (en) 2007-06-21
JP4809227B2 (ja) 2011-11-09
EP1670918A1 (de) 2006-06-21
CA2537340A1 (en) 2005-04-07
EP1670918B1 (de) 2009-11-11

Similar Documents

Publication Publication Date Title
ATE448312T1 (de) Leitsequenzen zur verwendung bei der produktion von proteinen
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
ATE541931T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE457355T1 (de) Verfahren und dna-konstrukte zur produktion von polypeptiden mit hoher ausbeute
DE602006011574D1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
ATE424457T1 (de) Menschliche stra6 polypeptide
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
CY1110546T1 (el) Μεθοδοι για παραγωγη μεγαλης κλιμακας πεδιου kringle 2 συν πρωτεαση σερινης (k2s) του πλασμινογονου σε προκαρυωτες
ATE329023T1 (de) Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäure
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
ATE337395T1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
ATE374825T1 (de) Verwendung von caspasen zur herstellung von reifen rekombinanten fusionsproteinen
DK1756273T3 (da) Signalpeptid til frembringelse af et polypeptid
PT1366161E (pt) Anticorpo anatagonista anti-pro842
NO20061858L (no) Ledersekvenser for anvendelse ved produksjon av proteiner
HUP0400915A2 (hu) Növényi reprodukciós proteinek
DE69932644D1 (de) Menschliches Protein mit in vitro antiproliferativer Aktivität.
ATE386129T1 (de) Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans
ATE380864T1 (de) Menschliches prostasin-ähnliches protein und dafür kodierende nukleinsäure
ATE402954T1 (de) Menschliches a33-antigen-ähnliches protein und dafür kodierende nukleinsäure
DE60043258D1 (de) Menschliches suppressor von fused
ATE447026T1 (de) Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties